Everolimus is an mTOR inhibitor that has shown promise for the treatment of complications associated with TSC including RAML, seizures, facial angiofibromas, and subependymal giant cell astrocytomas (SEGAs) (6–9). Here, MTOR is linked to tuberous sclerosis.